– USA, NC – Brii Biosciences Limited (HKG: 2137), a multi-national company developing innovative therapies today announced the appointment of Dr. Taiyin Yang (Ph.D.) to its Board as an Independent Non-Executive Director, effective September 1, 2022.
“We’re pleased to welcome Taiyin, an industry giant and admired leader, to our Board of Directors. Her extensive industry experience in product development and commercial manufacturing will provide important synergies as we continue the accelerated corporate growth,” said Chairman and CEO, Dr. Zhi Hong.
Concurrently, Dr. Yang will also join the Audit and Risk Committee as co-chair.
Dr. Zhi Hong added: “As part of Taiyin’s appointment, we will be enhancing our risk oversight and corporate governance through the newly expanded Audit and Risk Committee, where her expertise in product development, manufacturing, and supply, as well as product quality management and risk oversight, will serve Brii and its shareholders well into the future.”
The company also announced that the non-executive director, Dr. Axel Bouchon will step down from the Board effective September 30, 2022.
About Dr. Taiyin Yang
Dr. Taiyin Yang is the former EVP of Pharmaceutical Development and Manufacturing at Gilead Sciences. She directed operations of process, device and formulation development, manufacturing, packaging, analytical operations, laboratory information systems and data science, quality assurance, regulatory affairs, CMC program management, product distribution, supply chain management, and site operations. Under her leadership, Gilead developed the world’s first HIV single tablet regimen and advanced numerous compounds from early-stage development to market, reaching millions of people around the world. Before joining Gilead in 1993, Dr. Yang worked at Syntex Corporation for more than a decade, where she contributed to the development and commercialization of more than 10 medicines.
In 2022, Dr. Yang was elected to the National Academy of Engineers. She is a member of the Expert Scientific Advisory Committee of Medicines for Malaria Venture and the scientific advisory board of Sionna Therapeutics. Dr. Yang also serves on the board of directors of Kodiak Sciences and Kronos Bio. Dr. Yang holds a Ph.D. in organic chemistry from the University of Southern California and a Bachelor of Science degree in chemistry from National Taiwan University.
“As a life-long public health advocate, I recognize and celebrate the importance of Brii’s values-based and patient-centric approach to R&D. I appreciate the challenges of finding novel therapies that have the potential to fill clear and significant unmet needs for patients, and I’m honored to offer my expertise in advancing Brii’s vision as an independent advisor,” said Dr. Taiyin Yang. “I look forward to partnering with my fellow members of the Board and the senior management team to contribute to Brii’s future success as a mission-driven company with a promising pipeline of public-health inspired patient solutions.”
About Brii Bio
Brii Biosciences Limited is a biotechnology company based in China and the United States committed to advancing therapies for significant infectious diseases, such as hepatitis B, COVID-19, human immunodeficiency virus infection, multi-drug resistant or extensive drug-resistant gram-negative infections, and other illnesses, such as the central nervous system diseases, which have significant public health burdens in China and worldwide.
For more information: https://www.briibio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
